<DOC>
	<DOC>NCT00960531</DOC>
	<brief_summary>The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Subjects randomized under previous 3134K12201 study (NCT00498602) and met all inclusion/and none of the exclusion criteria. Screening brain MRI scan is consistent with the diagnosis of AD. MiniMental State Examination (MMSE) score greater than or equal to 10. Other criteria apply. Significant Neurological Disease other than Alzheimer's disease. Current clinically significant systemic illness. Other exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>